January 16, 2009 / 8:40 PM / 11 years ago

US FDA clears CSL bleeding disorder therapy

WASHINGTON, Jan 16 (Reuters) - Australian company CSL Ltd (CSL.AX) won U.S. approval on Friday to sell a treatment for a bleeding disorder seen in patients with a rare genetic defect.

The Food and Drug Administration cleared the product, Riastap, for people with congenital fibrinogen deficiency. Patients with the disorder are at risk of life-threatening bleeding without treatment, the FDA said. (Reporting by Lisa Richwine)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below